Overall Score

Growth

Revenue base remains low-multiple at 0.17x sales, but the company is still not demonstrating durable top-line growth.

Operating margins are positive at 10.2%, yet net margin remains negative at -4.0%, limiting evidence of scalable earnings growth.

No material change this month.

Profitability

Gross margin is 20.8% and EBITDA margin is 7.7%, but pretax margin is still negative at -4.6%.

Return metrics remain weak, with ROE at -16.5% and ROA at -2.1%, indicating limited compounding quality.

No material change this month.

Financial Health

Liquidity is acceptable with a current ratio of 1.62 and quick ratio of 1.09.

Leverage remains very high, with debt-to-equity at 6.5x and net debt to EBITDA at 14.6x, which constrains flexibility.

Interest coverage is only 1.19x, leaving little cushion if operating performance softens.

Valuation

The stock screens inexpensive on sales and cash flow, at 0.17x sales and 4.2x free cash flow.

Price-to-book is 0.74x and price-to-fair-value is also 0.74x, suggesting the market is discounting the balance-sheet and earnings risk.

Negative earnings keep P/E unhelpful, so valuation support depends on cash generation and debt reduction.

Durability

The business generates cash, but the cash conversion cycle is still long at about 101.7 days, reflecting working-capital drag.

Inventory days are elevated at 101.8, which can pressure resilience if demand weakens.

High leverage and negative profitability reduce long-term durability despite positive operating cash flow.